SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001558370-23-001179
Filing Date
2023-02-13
Accepted
2023-02-13 16:30:39
Documents
12
Period of Report
2023-02-10
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K sgtx-20230210x8k.htm   iXBRL 8-K 35948
  Complete submission text file 0001558370-23-001179.txt   159338

Data Files

Seq Description Document Type Size
2 EX-101.SCH sgtx-20230210.xsd EX-101.SCH 2951
3 EX-101.LAB sgtx-20230210_lab.xml EX-101.LAB 16579
4 EX-101.PRE sgtx-20230210_pre.xml EX-101.PRE 10453
6 EXTRACTED XBRL INSTANCE DOCUMENT sgtx-20230210x8k_htm.xml XML 5047
Mailing Address 100 BINNEY STREET STE 600 CAMBRIDGE MA 02142
Business Address 100 BINNEY STREET STE 600 CAMBRIDGE MA 02142 617-336-7540
Sigilon Therapeutics, Inc. (Filer) CIK: 0001821323 (see all company filings)

IRS No.: 474005543 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39746 | Film No.: 23618986
SIC: 2834 Pharmaceutical Preparations